Evaluation of the efficacy of olapatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model

This publication has 12 references indexed in Scilit:

• Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
  Ophthalmology, 2000
• Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model
  Clinical Therapeutics, 2000
• A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model
  Clinical Therapeutics, 2000
• A Current Appreciation of Sites for Pharmacological Intervention in Allergic Conjunctivitis: Effects of New Topical Ocular Drugs
  Acta Ophthalmologica Scandinavica, 1999
• Comparative Evaluation of Olopatadine Ophthalmic Solution (0.1%) Versus Ketorolac Ophthalmic Solution (0.5%) Using the Provocative Antigen Challenge Model
  Acta Ophthalmologica Scandinavica, 1999
• Inhibition of Histamine-Induced Human Conjunctival Epithelial Cell Responses by Ocular Allergy Drugs
  Archives of Ophthalmology (1950), 1999
• Evaluation of Olopatadine, a New Ophthalmic Antiallergic Agent with Dual Activity, Using the Conjunctival Allergen Challenge Model
  Annals of Allergy, Asthma & Immunology, 1998
• TheIn VitroandIn VivoOcular Pharmacology of Olopatadine (AL-4943A), an Effective Anti-Allergic/Antihistaminic Agent
  Journal of Ocular Pharmacology and Therapeutics, 1996
• Conjunctivitis of allergic origin: Immunologic mechanisms and current approaches to therapy
  Survey of Ophthalmology, 1993
• Conjunctival Allergen Challenge
  Archives of Ophthalmology (1950), 1990